country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-183119

Copy Link Print Information

Legumain-IN-2

Legumain-IN-2 is a selective legumain inhibitor with a human legumain IC₅₀ of 0.9 nM. Legumain-IN-2 can be used for the research of breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1609690-02-9
Formel: C₂₅H₂₈N₄O₅
Molecular Weight:464.51

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Legumain-IN-2 Chemical Structure

CAS. Nr.: 1609690-02-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Legumain-IN-2 is a selective legumain inhibitor with a human legumain IC₅₀ of 0.9 nM. Legumain-IN-2 can be used for the research of breast cancer^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	100 nM Compound: 7u	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 24775305]
T47D	IC₅₀	100 nM Compound: 7u	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 24775305]

In Vitro

Legumain-IN-2 (Compound 7u) potently inhibits recombinant human Legumain with an IC₅₀ of 0.9 nM^[1].
Legumain-IN-2 (30 μM) is highly selective for Legumain, showing minimal to moderate inhibition of other tested cysteine proteases^[1].
Legumain-IN-2 (30 μM; 120 h) reduces cell count by >70% in MCF7 and T47D breast cancer cells, but has no effect on MCF10a and HME-1 normal breast cell viability under the same conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human breast cancer cell lines MCF7, T47D; normal human breast cell lines MCF10a, HME-1
Concentration:

30 μM
Incubation Time:

120 h
Result:

Reduced cell count by >70% in MCF7 and T47D breast cancer cells compared to vehicle control.
Had no impact on cell viability in MCF10a and HME-1 normal breast cell lines.

Chemical Information

CAS. Nr. 1609690-02-9
Molecular Weight 464.51
Formel C₂₅H₂₈N₄O₅
SMILES

NC(C[C@@H](C#N)NC([C@H]1N(CCC1)C(OCC2=CC=C(C3=CC(OCC)=CC=C3)C=C2)=O)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Higgins C, et al. P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorg Med Chem Lett. 2014;24(11):2521-2524. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen